With regard to BCR signaling inhibition, fostamatinib, a SYK inhibitor, showed activity against relapsed DLBCL in an early phase I/II study [11], and evaluable tumor responses were observed in two of seven DLBCL patients treated with the BTK inhibitor, ibrutinib, as part of a phase I study for relapsed or refractory B-cell non-Hodgkin lymphoma [12]. The gene discussed is BTK; the disease is diffuse large B-cell lymphoma.